Introduction: Plaque psoriasis is a chronic skin disease where genital involvement is relatively common. Yet health care providers do not routinely evaluate psoriasis patients for genital involvement and patients do not readily initiate discussion of it. Methods: A qualitative study of 20 US patients with dermatologist-confirmed genital psoriasis (GenPs) and self-reported moderate-to-severe GenPs at screening was conducted to identify key GenPs symptoms and their impacts on health-related quality of life (HRQoL). Results: Patients had a mean age of 45 years, 55% were female, and patients had high rates of current/recent moderate-to-severe overall (65%) and genital (70%) psoriasis. Patients reported the following GenPs symptoms: genital itch (100%), discomfort (100%), redness (95%), stinging/burning (95%), pain (85%), and scaling (75%). Genital itching (40%) and stinging/ burning (40%) were the most bothersome symptoms. Impacts on sexual health included impaired sexual experience during sexual activity (80%), worsening of symptoms after sexual activity (80%), decreased frequency of sexual activity (80%), avoidance of sexual Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 62CCF0604618A478.
relationships (75%), and reduced sexual desire (55%). Negative effects on sexual experience encompassed physical effects such as mechanical friction, cracking, and pain as well as psychosocial effects such as embarrassment and feeling stigmatized. Males reported a higher burden of symptoms and sexual impacts. Other HRQoL impacts were on mood/emotion (95%), physical activities (70%), daily activities (60%), and relationships with friends and family (45%). These impacts significantly affected daily activities. Physical activities were affected by symptoms and flares, and increased sweat and friction worsened symptoms. Patients reported daily practices to control outcomes. Conclusion: The high level of reported symptoms and sexual and nonsexual impacts reflects the potential burden of moderate-to-severe GenPs. GenPs can impact many facets of HRQoL and providers should evaluate their patients for the presence of genital psoriasis and its impact on their quality of life. Funding: Eli Lilly and Company.
PLAIN LANGUAGE SUMMARY
Background: Psoriasis is a skin disease that can cause itchy, raised red patches of skin. Currently, psoriasis cannot be cured but medicines can make the patches smaller or go away completely. The patches can occur anywhere on the body. Sometimes people get them in their genital area. However, people are sensitive about this area and may not tell their doctor. Their doctor may not look or ask either. What We Did: We interviewed 20 men and women who had moderate-to-severe genital psoriasis. We asked about their health-related quality of life, including their sex life. What We Learned: All 20 people said they had symptoms of itching and discomfort in their genital area. Most people also had symptoms of redness, stinging or burning, pain, and scaling (flaky skin). Most people said symptoms affected their sex life. Sexual activity was less comfortable. People had sexual activity less often. Physical reasons, such as pain, bothered some people. Emotional reasons, such as being embarrassed, bothered other people more. People said the genital psoriasis affected how they felt. For example, it made them stressed, angry, or sad. Genital psoriasis made physical activities such as walking and running more uncomfortable for many people, especially when symptoms ''acted up.'' Sweating a lot, wearing tight underwear, or working a long day could make symptoms worse too. About half the people spent less time with their family and friends because of their symptoms. People also did things to try to reduce their symptoms. Some people wore loose clothes or soaked in a bathtub every night or after sex. Other people carried cream (to stop the itch) with them all the time. Conclusion: Other people may not experience what these 20 people did. However, having genital psoriasis can significantly impact someone's life. Patients and doctors should talk about it.
INTRODUCTION
Plaque psoriasis is a chronic inflammatory skin disease which can affect multiple body areas with different degrees of severity. Involvement of the genital area at some point in the disease course is relatively common. Many patients with psoriasis (32%-63%) reported current or past genital involvement in survey-based research [1] [2] [3] [4] [5] , and 38% had current genital involvement confirmed by physical exam [5, 6] . The unique microenvironment of moisture, warmth, and friction can lead to fissures, erosion, and maceration, and can also reduce the appearance of scaling [7] [8] [9] [10] . Red thin plaques and lack of scale are characteristic of genital psoriasis (GenPs) and can lead to misidentification by the patient (e.g., a sexually transmitted disease) and by health care providers (e.g., dermatitis or tinea) [9, 11, 12] .
Compared to psoriasis patients without genital involvement, psoriasis patients with genital involvement report statistically significantly worse health-related quality of life (HRQoL) [3, 5] and statistically significantly greater impact on sexual health and relationships [5, 13] . Women with genital psoriasis reported statistically significantly higher sexual distress than women without it [3] . Psoriasis patients with involvement of ''sensitive'' regions (the lower abdomen and genitals) report greater feelings of stigmatization compared to patients with visible hand, scalp, neck, and facial lesions [14] . However, despite this impact of genital symptoms, patients frequently do not broach the subject with their health care providers [4, 13] . Similarly, providers neither commonly question nor examine patients for its presence [3, 15] . More detailed descriptions from patients on the impact of GenPs may help encourage providers to identify and ultimately appropriately treat patients with GenPs. A qualitative study was undertaken of patients with GenPs to identify key GenPs symptoms and their impact on HRQoL from the patients' perspectives.
METHODS

Study Design
This was a cross-sectional, qualitative study of 20 male and female patients with GenPs. A targeted literature review and input from two US-based clinicians specializing in dermatology and research into general psoriasis and GenPs (authors CR and SF) led to the development of the draft conceptual model which underlies the semi-structured interview guide. The model ( Fig. S1 in the Electronic supplementary material, ESM) asserts that (1) GenPs symptoms influence short-term functional outcomes and (2) these short-term functional outcomes have distal impacts, including sexual and social endpoints.
The interview comprised two components: concept elicitation and cognitive interviews. During concept elicitation, patients were asked an open-ended question about the GenPs symptoms they experienced (without any definition of symptoms) and were then probed for more detail on the symptoms they reported as well as on predefined symptoms of itching, pain, scaling, discomfort, redness, and stinging/ burning, whether spontaneously reported or not. The same pattern was followed for sexual health and HRQoL: open-ended questions followed by specific topic probes. Predefined sexual health topics were sexual desire, sexual experience, sexual frequency, worsening of symptoms after sexual activity, and avoidance of sexual relationships. Predefined HRQoL topics were physical activities, mood or emotional status, social or leisure activities, work/ school, daily activities, and relationships with family/friends. Responses were both spontaneous and probed. During the cognitive interviews, patients completed two draft patient-report outcomes (PRO) measures, the Sexual Function Questionnaire and Genital Psoriasis Symptom Severity, and were asked for their feedback on the measures. Data from these two PROs will be covered in separate manuscripts. The study was conducted in accordance with the Declaration of Helsinki, good clinical practice, and all applicable laws and regulations. Although informed consent and institutional review board (IRB) oversight were waived by the local IRB (Chesapeake IRB, Columbia, MD), all participants gave written and verbal informed consent prior to commencing the interview.
Patient Recruitment
Patients were recruited in the continental USA by clinical staff from five clinical sites located in four states (Arkansas, Indiana, Michigan, and Washington). Clinical staff identified potential participants through review of clinical charts and screened them for study eligibility either in person or over the telephone. All patients had current or past GenPs confirmed by a dermatologist. At the time of screening, eligible adults (C 18 years) required a physician diagnosis of chronic plaque psoriasis (C 6 months duration); current or recent history (within 3 months) of moderate or severe genital involvement (per Patient Global Assessment C 4, 6-point scale from 0 to 5); confirmation by a dermatologist of overall psoriasis, affected body surface area C 1%, and plaque psoriasis in extragenital areas; and intolerance of or failure to respond to C 1 topical therapy, which included over-the-counter topicals, for GenPs.
Data Collection
A sample of up to 25 male and female patient interviews was proposed. One-on-one interviews were conducted and patients could choose to be interviewed in-person or on the telephone. Interviews were conducted between August 19, 2015 and November 19, 2015 by trained Evidera research associates (2 females [PhD, BS], 1 male [MS, RPh]), including JLP, PhD (author). Patients were asked if they preferred a gender-matched interviewer or had no preference, and a preference, when expressed, was matched when possible. All interviewers had at least 18 months' experience in the conduct of qualitative interviews and had received specific training for this study protocol. Prior to telephonic interviews, packets containing the informed consent form were mailed to subjects. Interviewers' reasons and interests in the research topic were described in the informed consent forms. Patients completed a brief sociodemographic questionnaire during the interview.
Each patient's interview was completed in one session lasting approximately 2 h. When finished, patients were remunerated for their time (estimated as fair market value). Upon completion of an interview, clinic site staff completed a clinical questionnaire on the medical history for each patient which included date of diagnosis with overall psoriasis and GenPs, affected body surface area, severity of GenPs, current GenPs status, and current GenPs medications. During the interview, GenPs was defined for women as symptoms of psoriasis that occur ''on the outer lip, the inner lip, and the area between your vagina and the anus'' and for men as ''the area of the penis, the scrotum, and the area between the penis and the anus.''
Data Analysis
The data for this paper focus largely on the concept elicitation interview component; the exception is that sex life satisfaction data derives from the Sexual Function Questionnaire administered during the cognitive interview component. All patient interviews were audio-recorded, transcribed by a third-party professional transcriber, and reviewed by the study team for quality assurance purposes. Personal health information was redacted and obvious transcription errors were corrected.
A content analysis approach was used to analyze the qualitative data (based on notes, transcripts, and audio recordings) from the interviews [16] . This approach uses empirical data to validate that measurement tools and their underlying conceptual framework are consistent with the experiences and perspectives of patients. Based on the semi-structured interview guide and further refined by additional specific details that emerged from the interviews, a coding dictionary was developed by a member of the research team (JLP). One research associate coded the transcripts and all coding was reviewed by JLP. A qualitative analysis software program, ATLAS.ti (version 7.5.9, Scientific Software Development GmbH, Berlin, Germany), was used by the study team to systematically identify and code themes within the transcripts which were then organized in chronological order by date of interview and tabulated to document and quantify the emergence of concepts related to the study objectives. Data were organized chronologically in order to determine the point at which saturation of concepts was reached. Saturation, the point at which gathering additional data does not yield additional new concepts, was reached with the 20 interviews. Descriptive statistics (mean, standard deviation, frequency) were used to characterize the sociodemographic and clinical characteristics of the population.
RESULTS
Patients
Of the 25 screened patients, 22 met the inclusion criteria. Two eligible subjects were unavailable for participation, and 20 patient interviews and clinical assessments were completed. All patients chose telephonic interviews and declined face-to-face meetings.
The mean age was 45 years (range 21-68), 55% (n = 11) were female, and 90% (n = 18) were white ( Table 1 ). The mean durations since diagnosis for overall psoriasis and GenPs were 18 and 7.5 years, respectively, but seven patients (35%) were diagnosed with overall psoriasis and GenPs during the same year, and the relative timing of their two diagnoses is unknown. At the time of their interview, in the 3 months prior, most patients (n = 13, 65%) reported current/recent moderate-to-severe overall psoriasis (n = 8, 40% rated it severe), and the majority (n = 14, 70%) reported current/recent moderate-to-severe GenPs (n = 6, 30% rated it severe). (Note that all patients met the study criteria at screening per the requirements of the protocol.) Current extragenital psoriasis was most common on the scalp (n = 17, 85%), ; these data report status at the time of the interview e Per interviewers' judgment, the question was not asked due to auditory cues, conversation flow, and patient's apparent lack of comfort with sensitive topics and hands, feet, and/or nails (n = 13, 65%) ( Table 1) . Seventy percent of patients were currently receiving at least one GenPs treatment which included biologics (n = 11, 55%) and topicals (n = 7, 35%).
Patient-Reported Genital Psoriasis Symptoms
Patients reported multiple genital symptoms. The most commonly reported were itch and discomfort (both n = 20, 100%), redness (n = 19, 95%), stinging/burning (n = 19, 95%), pain (n = 17, 85%), and scaling (n = 17, 75%) ( Fig. 1a ). Thirty percent (n = 6) of patients reported cracking. Patients also reported flaking (n = 4, 20%), dry skin (n = 3, 15%), pimples (n = 2, 10%), being more susceptible to illness (n = 2, 10%), bleeding, inflammation, irritation, mental discomfort, oozing, bad odor, and swelling (each n = 1, 5%). Of these, the ''most bothersome'' symptoms (patients could report C 1 symptom) were itch and stinging/burning (both n = 8, 40%). Qualitatively, gender differences were observed. All females (n = 11, 100%) reported experiencing itch and discomfort, whereas all males (n = 9, 100%) reported itch, discomfort, redness, stinging/burning, and pain ( Fig. 1a ). Half of females reported itch as the most bothersome symptom (n = 6, 55%) ( Fig. 1b) whereas males reported stinging/burning as the most bothersome symptom (n = 4, 44%) ( Fig. 1c ).
Differences Between Genital and Nongenital Psoriasis Symptoms
Most patients (n = 18, 90%) reported that some aspect of GenPs was more intense and/or unique compared to extragenital psoriasis (see Table 2 for representative patient quotations). Several features were identified. First was the constant intensity of, awareness of, and/or need to manage a symptom in GenPs versus in other locations. Itching was commonly reported for its intensity, and in some cases patients scratched until bleeding occurred. Second was the sensation of pain, particularly that linked to itching. The pain sensation could have the effect of limiting sexual activity and social life (below). Finally, two patients reported feeling self-conscious that their GenPs might be misidentified as a sexually transmitted disease. Patients attributed the differences with GenPs as due to thinner, more tender skin, more moistness and sweat, greater impact from sweat, increased friction from skin or clothes, and topical treatments not lasting as long. 
Effect of Genital Psoriasis on Sexual Activity
A higher percentage of men reported being ''currently sexually active'' than women (67% versus 27%). GenPs affected many aspects of sexual health. Nearly all patients (n = 18, 90%) reported at least one negative impact on sexual activity. These included impaired sexual experience during sexual activity (n = 16, 80%) (defined broadly to include intercourse and activities such as masturbation), worsening of symptoms after sexual activity (n = 16, 80%), decreased sexual frequency (n = 16, 80%), F female, M male, STD sexually transmitted disease Semi-structured interviews were conducted with 20 patients with genital psoriasis. Selected quotations are from patients and have been edited to minimize repetitive language avoidance of sexual relationships (n = 15, 75%, which men reported more frequently than women, 89% vs 64%), and reduced sexual desire (n = 11, 55%) ( Fig. 2a ). In the week prior to the interview, half of patients reported that GenPs affected their sex life satisfaction ''quite a bit'' or ''very much'' (each n = 5, 25%), 30% (n = 6) responded ''not at all,'' 10% (n = 2) reported ''somewhat,'' 5% (n = 1) reported ''a little bit'','' and 1 patient (5%) had not had GenPs symptoms in the past week. Nearly half (45%) of patients reported sexual inactivity (Table 1) , but they were not asked if the current inactivity was related to GenPs or another reason.
Negative effects on sexual experience encompassed physical effects such as mechanical friction, cracking, and pain and psychosocial effects such as embarrassment and feeling stigmatized. The physical effects could linger for hours, if not days, as prolonged pain and discomfort. This led some patients to intervene with immediate self-made treatments (such as bathing in Epsom salts) to control post-activity symptoms. Some patients described proactively weighing the value of a potential intimate encounter against its potential subsequent pain and discomfort. Not surprisingly, decreases in frequency and avoidance of sexual relationship were common. Patients not in relationships described embarrassment or a reluctance to reveal their GenPs to someone, and those in long-term relationships, even with understanding partners, described the emotional toll their avoidance incurred on the relationship (quotations in Table 3 ).
Effect of Genital Psoriasis on Nonsexual Aspects of HRQoL
GenPs led to impairment of HRQoL beyond sexual health, including on mood/emotion (n = 19, 95%), physical activities (n = 14, 70%), daily activities (n = 12, 60%), social or leisure activities (n = 9, 45%), relationships with friends and family (n = 9, 45%), and work or school (n = 7, 35%) ( Fig. 2b) . Patients reported feeling stressed, frustrated, angry, anxious, depressed, sad, and embarrassed due to GenPs, which could trigger distraction, self-consciousness, lowered self-esteem or confidence, feeling less desirable, helplessness hopelessness, concern for the future, and wondering ''why me?''
The physical component was affected by symptoms and flares which inhibited physical activities (such as walking, running, or swimming in chlorinated pools), and by increased friction and sweat (e.g., a longer work day, increased sweating from exertion or weather conditions, or not being able to treat symptoms promptly). Even sitting was reported to be Per interviewers' judgment, the question was not asked of two patients due to auditory cues, conversation flow, and the patients' apparent lack of comfort with sensitive topics uncomfortable by some patients. Other factors which worsened GenPs included stress, dryness in winter, lack of sleep, and drinking alcohol. The impairments led patients to eliminate certain physical activities, reduce intensity, or limit the number of activities in a day (quotations in Table 4 ).
These impacts significantly affected daily activities, such as painful urination and poor sleep hygiene due to difficultly in falling asleep 
Representative patient quotations
Mood/emotion
The pain brings on discomfort and then it just triggers everything else, the stress and the anxiety and emotions and everything… It all just works together against me. and unconscious scratching while sleeping.
Patients reported many common practices in their daily life to control symptoms. These included, for example, choosing loose-fitting clothes based on comfort, daily routines of a shower or soaking bath, needing to carry certain supplies (e.g., ointments and creams to treat symptoms, panty liners because of oozing), or taking specific precautions (e.g., a male patient wrapped his penis in tissue paper during periods of post-cracking hypersensitivity). These HRQoL impairments led to decreased interactions with family and friends and social networks as some patients reported that their symptoms lead them to be nonsocial (e.g., fear of itching badly and not being able to scratch in social situations, fear of nakedness in front of others, etc.) (quotations in Table 4 ). Patients also described learning to cope with their GenPs, which included finding treatment regimens and routines that reduced symptoms and improved their quality of life.
General Themes
General themes emerged. A first theme was the constant intensity and/or awareness of some aspects of GenPs, such as itching, friction, or symptoms that repeated themselves in a continuous cycle. A second theme was that GenPs presented some different challenges than extragenital psoriasis (i.e., intensified sensation of pain or discomfort and being associated with the stigma of sexually transmitted diseases). A third was the toll of GenPs on sexual life and relationships, whether in actual or potential situations. The final theme was the mental and emotional strain of GenPs. Patients spoke of being distracted during social interactions, isolating themselves, needing to be always vigilant in their efforts to control symptoms, and learning to ignore their symptoms and ''turn it off'' and ''not let it get me down.''
DISCUSSION
This qualitative study of patients with moderate-to-severe GenPs showed that GenPs led to multiple specific psychosexual and psychosocial impairments. Symptoms were reported to be more intense and/or constant in GenPs than in extragenital psoriasis, and nearly all patients reported negative impacts on both sexual and nonsexual quality of life. The disproportionate impact of GenPs has been recognized by some treatment and consensus guidelines. Due to the physical, emotional, and social burden of GenPs on patients, guidelines for the treatment of psoriasis suggest that even in patients with low body surface area involvement, involvement of genital skin may justify its classification as moderate or severe disease and thus warrant systemic treatment, especially if topical treatments are ineffective [17, 18] . Table 4 continued
Representative patient quotations
Personal relationships I was embarrassed and thought there was something wrong with me…I had all these concerns…that no one will ever want me. I won't be able to have a girlfriend or wife. (M) I'm not social any more. I've become a recluse…if it starts itching or something…it's not seemly that you would be able to take care of yourself in a public situation. (F) It's not like I ever want to be naked around anyone when that's going on. So from showering in a locker room to in a relationship, it puts you on a more guarded and different level. (M) Semi-structured interviews were conducted with 20 patients with genital psoriasis. Selected quotations are from patients and have been edited to minimize repetitive language F female, M male
The level of reported symptoms in this study was high. The majority of our patients reported current/recent moderate-to-severe GenPs, and the high level of reported GenPs symptoms likely reflects this disease burden. In terms of reported symptoms, all patients reported itch, which is common to GenPs patients [12] as well as to patients with extragenital psoriasis (77%-88%) [19] [20] [21] . Itch was also reported as one of the most bothersome symptoms, consistent with the study by Meeuwis and colleagues [4] in which GenPs patients reported itch and redness had the ''highest intensity.'' The impact of GenPs described by patients in this study was pronounced. Patients with plaque psoriasis in extragenital locations already report impairment of sexual health [22] [23] [24] [25] , but the presence of GenPs incurs an additional toll [3, 5] . This current study sheds light on the impact of high GenPs disease burden on multiple aspects of sexual experience and relationships. The reported high level of nonsexual impacts, particularly on mood/emotions, physical activities, and daily activities, is supported by the findings of more severe impairment on HRQoL [3, 5] and greater depression [5, 13] in psoriasis patients with versus without genital involvement. Psoriasis patients with pain experience interference with function significantly more frequently and more severely compared to patients with skin discomfort [26] . The high rates of reported pain and discomfort in this study underscore their impact on emotions and daily life.
Interesting differences were observed between men and women in this study. Men not only reported a higher symptom frequency burden than women, but 8 of the 9 men also reported significant sexual impacts. The most bothersome symptoms differed, with itch being most bothersome for women and stinging/ burning most bothersome for men. These findings may reflect the higher prevalence in this study of cracking in men or biological and/or psychological differences between the genders [4] . Despite their higher burden, men reported a higher level of sexual activity and greater avoidance of sexual relationships than women, which could suggest that more men maintained sexual activity through masturbation.
One important finding was the time lag between mean diagnosis of general psoriasis and GenPs, with the diagnosis of extragenital psoriasis predating that of GenPs for many patients. Given that estimates of the proportion of psoriatic patients with a current or past history of GenPs range from 32% to 63% [1] [2] [3] [4] [5] , patients with psoriasis are at risk for developing GenPs. The disease currently engenders reluctance amongst patients and even some health care providers to discuss it or physically examine the genital area, yet it can significantly impact many facets of patient quality of life. Providers should consider genital involvement as a possibility in patients with psoriasis and provide appropriate follow-up.
The extent to which these findings can be generalized to all GenPs patients may be limited. The overall sample size (N = 20) and gender subgroups (11 females and 9 males) were small and geographically limited to four states in the continental US. Racial minorities were underrepresented. Sexual identity was not elicited during the interview and the perspectives of patients in same-sex relationships or transgender patients were not explicitly represented. Recruitment occurred in clinics and patients not seeking allopathic care were underrepresented. Patients with greater impairments may be more inclined to share their experience, leading to selection bias, and other biases during the interviews or data interpretation could have come into play. The finding that all patients preferred telephone, rather than face-to-face, interviews leads the authors to speculate that the social distance afforded by the telephone may reflect patients' embarrassment or discomfort.
CONCLUSIONS
In conclusion, this qualitative study of patients with high rates of moderate-to-severe GenPs reported multiple psychosexual and psychosocial impairments from their GenPs symptoms. The details of patients' ''lived experience'' in illuminating the burden and impact of GenPs attests to a role for qualitative research in psoriasis research [19, 27] . Given the chronic nature of psoriasis, providers may want to consider that patients with psoriasis may have or could develop genital involvement. Future studies should look at treatments which help patients with GenPs maintain or achieve a higher level of quality of life and sexual functioning. Additionally, studies are needed to examine the factors involved in the reluctance of health care providers and patients to discuss GenPs and its impact on HRQoL. Lastly, patients' subjective quality of life is an important factor in determining appropriate treatment and should be considered in addition to the total body surface area of involvement.
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